Recording: Artificial Intelligence: Evolution, Challenges and Opportunities for Supportive Care in Cancer

Recorded November 14, 2024 From the early work of British mathematician Alan Turing in the 1930s, Artificial Intelligence has steadily evolved until most recently, when there has been a veritable explosion to apply AI solutions in multiple sectors, including healthcare. This evolution has taken several paths, and the journey has not been without challenges. This webinar took participants through the AI journey, and the discussion focused on these challenges and opportunities for AI in supportive oncology. Participants will gain an understanding of: • The evolution of AI • Application of AI “types” in healthcare generally and oncology specifically • AI Challenges: application and deployment • Opportunities for AI in Supportive Oncology Featured Speaker Fred Ashbury, PhD, MACE, Chief Scientific Officer, VieCure, Denver CO US • 30+ Years of Cancer Leadership Experience • Former CSO with OpTx Corp • Former Senior Executive with Cancer Care Ontario and Alberta Cancer Board Fred is a co-founder and Chief Scientific Officer at VieCure. He is responsible for developing, maintaining, and codifying VieCure’s oncology clinical content knowledge base, and the design and implementation of the diagnostic, treatment, supportive care and post-treatment rehabilitation and survivorship rules that underpin VieCure’s platform. With colleagues, Fred holds the only patented Artificial Intelligence decision-support platform in healthcare (US Patent No. 17,798,689 B2): “Capability to Create Personalized Healthcare Treatment Plans for Individuals with Medical Conditions.” He received his bachelor’s degree (honours) from the University of Toronto, his master’s degree from Queen’s University, and his doctorate from York University. Fred’s career focus has been medical oncology and behavioral sciences. He is a former senior executive with the National Cancer Institute of Canada, Cancer Care Ontario, the Alberta Cancer Board, OpTx Corporation, and BridgeSite Clinical Research.